Overview of Propyleenglycol

Property	Description
Active Ingredient	Not applicable; functions as an excipient
Form	Viscous Liquid component of solutions, creams, and injectables
Pharmacological Class	Pharmaceutical Excipient; Organic Solvent; Glycol
Common Use	Solubilizing and stabilizing active drugs
Origin	Synthetic substance

Propyleenglycol, chemically known as 1,2-Propanediol, is a clear, viscous, and odorless synthetic substance that is structurally classified as a glycol (a 1,2-diol). It functions in medicine primarily as an excipient, meaning it is an inactive ingredient essential for formulating the final drug product, rather than the ingredient that produces a therapeutic effect.

Propylene Glycol: Chemical Identity and Classification

Propyleenglycol is a synthetic substance synthesized for purity and consistency, and is classified chemically as an organic solvent within the broader polyol group. This controlled, non-natural origin ensures strict quality standards required for its role in medicine. The substance's inherent hygroscopic nature, meaning it readily attracts and retains water, is a key attribute utilized in its pharmaceutical function. 1,2-Propanediol is used as a solvent, emulsifier, and humectant in drug preparations. This supports the recognition of Propyleenglycol's ability to help stabilize and blend the different components of a medicine.

What Type of Ingredient is Propyleenglycol in Medicine?

Propyleenglycol's core role is that of a pharmaceutical excipient, serving as a co-solvent and diluent that is combined with the active pharmaceutical ingredient (API). It is a common component in a wide variety of preparations, including liquid oral solutions, topical formulations (creams and ointments), and certain parenteral products (injectables). It is utilized in various non-active roles across numerous formulations. This designation reflects its status as an essential supportive ingredient, commonly found across formulations intended for adults and specific pediatric preparations where solubility challenges exist.

General Purpose: Why is Propyleenglycol Necessary?

Propyleenglycol is necessary primarily to ensure the solubility and stability of the active medicine, which is its fundamental purpose. It achieves this by acting as a powerful solubilizer, allowing drug molecules that do not easily dissolve in water to be uniformly dispersed throughout the preparation, guaranteeing accurate dosage delivery. In creams and lotions intended for topical use, its humectant property helps maintain moisture and prevents the formulation from drying out or degrading, contributing to the product's longevity and consistency. Propyleenglycol is characterized by its established profile as a pharmaceutical additive for these purposes.

What side effects are possible with Propyleenglycol?

Propyleenglycol is a pharmaceutical excipient whose safety profile is well-defined in regulatory documents, with adverse reactions generally associated with conditions leading to systemic accumulation. This accumulation typically occurs following high-dose or prolonged exposure, particularly via intravenous administration, or in individuals with reduced capacity to clear the substance.

Serious Systemic Adverse Reactions

The most serious reactions documented in official sources relate to systemic toxicity and are grouped under specific System-Organ Classes (SOC). These include Metabolism and nutrition disorders such as lactic acidosis and hyperosmolality. Serious effects may also involve Renal and urinary disorders (acute kidney injury), Nervous system disorders (CNS depression, seizures, and coma), and Cardiac disorders (cardiac arrhythmia and cardiotoxicity). Other documented effects are linked to Blood and lymphatic system disorders, such as hemolysis.

General and Population-Specific Safety Notes

General adverse effects associated with exposure include contact dermatitis, skin irritation, nausea, and headache. Regulatory guidance highlights increased risk in specific populations due to diminished clearance. Neonates and children under four years are explicitly noted to be at elevated risk of accumulation and toxicity due to the immaturity of their metabolic and renal pathways. Patients with underlying hepatic or renal impairment are also formally identified as being more vulnerable to Propyleenglycol accumulation. Furthermore, certain high-level safety notes include the potential for increased accumulation risk when used concurrently with specific medications, such as metronidazole.

Overdose and Emergency Response

Overdose and when to Seek Help: Official Regulatory Information

Propylene Glycol (PG) overdose is defined by accumulation toxicity resulting from high-dose or prolonged exposure, particularly when the body's clearance mechanisms are impaired. Officially documented clinical manifestations of toxicity involve severe effects on vital physiological systems. CNS effects can include depression, seizures, and coma. Cardiovascular effects may present as cardiac arrhythmia and hypotension, alongside respiratory depression. Metabolic abnormalities are common, specifically lactic acidosis, metabolic acidosis, and hyperosmolality. Severe outcomes include acute renal failure and liver dysfunction.

A heightened risk of accumulation toxicity is officially noted in neonates and infants due to their reduced metabolic and renal clearance. Individuals with pre-existing impaired renal or hepatic function are also at increased risk. In the event of a suspected overdose, immediate medical advice must be sought to manage the symptoms. Regulatory documentation states that no specific antidote is known, making the required medical approach symptomatic and supportive treatment. Medical monitoring is required to manage these life-threatening events.

Therapeutic Uses of Propyleenglycol

Main Uses and Benefits of Propylene Glycol in Medicine

Propylene Glycol (PG) is a crucial pharmaceutical excipient, meaning it is primarily used as an inactive ingredient to support the delivery and functional stability of active drugs, rather than having a direct therapeutic effect itself. Its main uses in medicinal products are highly versatile, covering multiple therapeutic domains.

PG is commonly used as a co-solvent in parenteral, oral, and topical formulations, which may assist with the formulation of certain medicinal products for conditions characterized by periods of heightened symptoms and conditions involving episodic or fluctuating manifestations. Furthermore, it also assists in managing certain symptoms related to physical discomfort. It functions in medicinal products as a co-solvent, a humectant, and a preservative.

PG is also applied in addressing symptoms related to physical discomfort and conditions involving inflammatory states by acting as a humectant (moisturizer) in topical preparations like creams and ointments. This contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability when symptoms interfere with routine activities.

“It is commonly used when short-term symptomatic assistance is needed and is relevant when supportive symptom management is appropriate.”

Quick Fact: Supports Easing Symptoms Related to Physical Discomfort

Regulatory References

European Medicines Agency (EMA) guidance on excipients

Eligibility and Restrictions for Use

Population Eligibility for Propylene Glycol (Excipient)

Eligibility for products containing Propylene Glycol (PG) is strictly governed by maximum daily exposure limits set by regulatory authorities, as PG is an excipient (inactive ingredient) with metabolism challenges in vulnerable groups.

Contraindications and Restrictions

Population Group	Eligibility Status	Regulatory Basis
Neonates (≤ 28 days)	Highly Restricted Use	Maximum exposure limit of 1 mg/kg/day due to immature clearance.
Children (1 month to < 5 years)	Restricted Use	Maximum exposure limit of 50 mg/kg/day.
Adults & Children (≥ 5 years)	Generally Allowed	Maximum general safety limit of 500 mg/kg/day.
Specific Infants/Neonates	Contraindicated	Prohibited for certain high-PG drug formulations (e.g., Lopinavir/Ritonavir oral solution) where safe limits are exceeded.

Conditional Use Requirements

Use requires special caution in patients with impaired liver or kidney function, as reduced organ capacity increases the risk of PG accumulation. Administration during pregnancy or lactation requires specific assessment, as PG is documented to reach the fetus and is found in breast milk. Additionally, the use of oral or injectable PG products in young children (< 3 years old) is generally restricted to a maximum duration of one week.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Propyleenglycol (PG) is a pharmaceutical excipient, and its officially documented interactions are primarily related to its metabolism. PG is metabolized by the enzyme alcohol dehydrogenase (ADH), and co-administration with other substances that utilize this pathway can lead to clinically significant interactions.

Metabolic and Exposure-Altering Interactions

Co-administration with ethanol (alcohol) or other ADH substrates may result in competitive inhibition of PG metabolism. This reduces clearance, leading to an increased systemic exposure and the risk of Propyleenglycol accumulation, as documented in regulatory reviews.

Formal Contraindications: Regulatory labeling for certain PG-containing oral solutions lists a formal contraindication for co-administration with ADH inhibitors such as disulfiram and metronidazole. These agents are prohibited due to the risk of severe reactions resulting from altered Propyleenglycol breakdown.

Timing and Population Restrictions

Administration restrictions mandate specific wash-out periods for contraindicated drugs. For example, disulfiram must be discontinued for a minimum of 14 days before starting the PG-containing product, and metronidazole must be avoided for at least 7 days after the treatment is concluded.

Interaction risk is officially documented to be heightened in specific populations. Neonates and children under 4 weeks of age have an increased risk of accumulation due to the immaturity of the ADH enzyme system. Patients with hepatic impairment (liver disease) or renal impairment (kidney disease) are also noted to be at increased risk due to potentially compromised clearance.

Mechanism of Action

Propylene glycol (PG) functions primarily as a pharmaceutical excipient, influencing drug performance through its inherent physical and chemical properties rather than direct modulation of biological targets like receptors or enzymes.

Lipid Bilayer Interaction and Permeation Modulation

PG engages the stratum corneum (SC) lipids. It penetrates the SC, intercalating into the lipid headgroup regions of the lipid bilayer. This molecular interaction disrupts the lateral packing and increases the mobility and disorder of the lipids. This mechanistic consequence results in an increase in drug molecule flux across the stratum corneum and into underlying biological matrices, modulating subsequent systemic exposure.

Solvency and Thermodynamic Activity

PG acts as a solvent and cosolvent in drug formulations, utilizing its amphiphilic structure. This property allows it to dissolve active pharmaceutical ingredients (APIs) that are poorly soluble in water, thereby increasing the thermodynamic activity of the drug within the dosage form. This capacity facilitates the maintenance of API concentration within the vehicle, influencing drug activity for subsequent biological interaction.

Humectant and Water Regulation

The molecule exhibits hygroscopic properties, engaging mechanisms that regulate water balance in formulations and on biological surfaces. As a humectant, it absorbs and retains moisture. This influences the hydric balance within biological matrices, a parameter relevant for the biophysical properties of surfaces like the epidermis.

Dosage and Administration Information

Propylene Glycol (PG) is an inactive ingredient classified as a pharmaceutical excipient, and its incorporation into drug products is governed by strict constraints that define its proper use. These constraints take the form of Maximum Daily Exposure (MDE) limits. This MDE represents the maximum quantity of the excipient that can be contained in all medicinal products administered to a patient within a 24-hour period.

PG is used as a co-solvent and stabilizer in a variety of preparations, including oral solutions, parenteral (IV) injectables, rectal, and topical formulations. The highest MDE limit is 500 mg/kg/day, which applies to adults and children 5 years of age and older, and is considered applicable for long-term use.

The MDE constraints are significantly reduced for younger patients due to limitations in metabolic capacity:

Population Group	Maximum Daily Exposure (MDE)
Adults and Children 5 years and older	500 mg/kg/day
Children (1 month to 4 years)	50 mg/kg/day
Neonates (28 days or younger)	1 mg/kg/day

Additionally, guidelines impose mandatory labeling requirements on oral and parenteral products when the Propylene Glycol content exceeds specific thresholds (400 mg/kg for adults; 200 mg/kg for children), serving as a special administrative condition of use. The overall use protocol for PG-containing medicines is defined by the requirement that the total daily load of the substance does not surpass these age-specific MDE limits.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Chronic Pain Management

Research has examined the drug for managing chronic, non-cancer pain, particularly in individuals who have not responded to initial treatments.

Studies investigated the drug's activity on voltage-gated calcium channels.

Most studies observed a change in pain severity ranging from 30–50% over a 12-week period. Initial studies reported that changes in pain levels were often observed within the first week of titration.

Comparative Studies

One study compared the drug’s effects on pain relief timing and magnitude against traditional NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Other investigations have explored its use alongside opioid medications; results suggested that this combination may be relevant for individuals with neuropathic components.

For nerve-related pain, research has evaluated the drug’s effects, with some findings showing changes in pain scores that were statistically significant compared to placebo.

Neuropathic Pain

Studies have evaluated the drug’s effects on conditions such as diabetic peripheral neuropathy and post-herpetic neuralgia. Studies suggest that the drug's activity may be associated with changes in nerve-related pain perception.

Epilepsy and Seizure Control

Studies evaluated the drug’s association with the frequency and intensity of seizures in adult patients with partial-onset seizures, with and without secondary generalization.

Tolerability and Safety Profile

Studies have assessed the long-term use and tolerability profile of the drug, including in specific populations. Research reports that abruptly stopping the medication may lead to adverse effects such as an increase in seizure frequency. Research has investigated the necessity of dose adjustments for individuals with kidney impairment. Observed effects in clinical trials included reports of dizziness, somnolence, and peripheral edema.

Frequently Asked Questions (FAQ)

Common questions about Propyleenglycol (FAQ)

Q: Why is Propyleenglycol included as an ingredient in so many different medicines?

A: Regulatory and excipient documents describe its frequent use due to its versatile functions. It is used primarily as a solvent to help dissolve active drug ingredients that do not mix well with water. It also functions as a stabilizer and a humectant (an agent that retains moisture) in the final medication formula.

Q: Is it true that Propyleenglycol can cause irritation in some users?

A: Yes, authoritative reports indicate that frequent skin exposure to products containing Propyleenglycol can potentially irritate the skin for some individuals. In addition, contact dermatitis, which is a form of skin inflammation or allergy, has been reported with its topical application.

Q: Can Propyleenglycol affect the way other ingredients in a medication are absorbed?

A: In some topical medications, Propyleenglycol can act as a penetration enhancer. This means it is used specifically to increase the permeation and absorption of the active drug ingredients through the skin barrier and into the body.

Q: What is the difference between Propyleenglycol and polyethylene glycol?

A: While both are excipients, official documentation often describes them based on their main function. Propyleenglycol is commonly used as a solvent and a humectant that retains moisture. In contrast, polyethylene glycol (PEG) is generally classified as a demulcent, meaning it forms a protective, soothing layer to relieve irritation.

Q: Why do some people worry about Propyleenglycol being in their products?

A: Official literature and regulatory reviews note that concerns relate to the risk of Propyleenglycol accumulation in the body, which may potentially lead to toxicity. This risk is primarily documented in specific, sensitive populations such as neonates and patients with impaired kidney or liver function.

Q: Are there known populations who are more sensitive to the effects of Propyleenglycol?

A: Yes, official regulatory documents state that an increased risk of accumulation is noted in neonates (newborns) and in patients with compromised liver or kidney function. This risk is due to potential issues with the body's natural metabolic breakdown and elimination processes.

Q: Why might a user feel a stinging sensation after applying a medication with Propyleenglycol?

A: Regulatory-related product texts indicate that minor feelings like burning, stinging, or irritation may temporarily occur when some products containing Propyleenglycol are first used. This sensation is generally described in product information as temporary.

Q: What is Propyleenglycol used for besides its main medical purposes?

A: Beyond medicine, Propyleenglycol has been classified by the U.S. Food and Drug Administration (FDA) as 'generally recognized as safe' (GRAS) for use as a direct food additive under certain conditions. It is also used as an ingredient in various cosmetics.

Q: What research evidence exists regarding Propyleenglycol's use in topical preparations?

A: Regulatory reviews summarize research themes related to its function as a penetration enhancer in topical products. Studies have examined its dermal absorption (how much is absorbed through the skin) and its potential to cause contact dermatitis (skin inflammation).

Q: Can Propyleenglycol be present in food or beverage products?

A: Yes, the U.S. FDA has classified Propyleenglycol as GRAS (generally recognized as safe) for use as a direct food additive under specified conditions of use. This is separate from its use as an excipient in medicinal products.

Q: Does the European Medicines Agency (EMA) have specific guidelines for Propyleenglycol?

A: Yes, the EMA has produced specific documents, including an Assessment Report, to provide official guidance on Propyleenglycol's use as an inactive ingredient. These documents establish important rules, such as the Maximum Daily Exposure (MDE) limits.

Q: Is Propyleenglycol a synthetic compound or is it naturally derived?

A: Official chemical and health agency sources describe Propyleenglycol as a synthetic liquid substance. It is not derived directly from natural sources.

Q: Are there different quality grades of Propyleenglycol used in medicines versus industrial products?

A: Yes, medicines must use a high-purity form, such as Propylene Glycol USP (United States Pharmacopeia) or an equivalent grade, which meets strict regulatory standards for quality and purity. These grades are distinct from those used in industrial applications.

Q: Do official documents mention any potential for Propyleenglycol to cause hypersensitivity reactions?

A: Reports mention the potential for contact dermatitis with topical application of the substance. Propyleenglycol has been cited in dermatological literature as a substance that may act as a contact allergen.

Q: How is Propyleenglycol generally processed by the human body?

A: Propyleenglycol is processed primarily by the liver and kidneys. Approximately 45% of the substance is excreted unchanged by the kidneys. The remaining amount is metabolized in the liver into compounds such as lactic acid and pyruvic acid.

Q: What does the term 'Propyleenglycol toxicity' generally refer to in a medical context?

A: In medical documentation, toxicity generally refers to adverse effects that can result from high systemic exposure and accumulation of the substance. These effects are documented to include serious concerns like lactic acidosis, hyperosmolality, and effects on the central nervous system.

Q: Is Propyleenglycol used as a preservative in any medicinal products?

A: Yes, Propyleenglycol is documented in excipient resources to function as a preservative in certain medicinal solutions and topical preparations. This is in addition to its more common roles as a solvent and humectant.

Q: What is the primary function of Propyleenglycol when included in eye drops?

A: When included in eye drops, particularly artificial tears, Propyleenglycol acts as a demulcent and a humectant. Its function is to help form a protective layer and retain moisture on the surface of the eye to provide relief.

Q: What are the official descriptive uses of Propyleenglycol in pharmaceutical compounding?

A: Official uses are described according to its role as an excipient. These include serving as a solvent (to dissolve ingredients), a cosolvent, a stabilizer (to maintain product consistency), and a humectant (to retain moisture) in various preparations.

Q: Does Propyleenglycol affect the central nervous system in any way?

A: High systemic exposure to Propyleenglycol, usually occurring only with very large amounts of medication, has been associated with effects on the central nervous system (CNS). These effects are documented as potentially including CNS depression, seizures, and coma in cases of severe accumulation.

Q: Is it common for Propyleenglycol to be used in nebulizer solutions?

A: Propyleenglycol is documented in pharmaceutical excipient literature as a solvent used in certain aerosol and liquid formulations. This includes its use in some nebulizer solutions.

Q: How long does Propyleenglycol stay in the body after administration?

A: In healthy adults with normal liver and kidney function, the mean elimination half-life (the time it takes for half of the amount to be cleared) is described in official reports as approximately 2.3 pm 0.7 hours after administration.

Q: Is Propyleenglycol used in vaccines?

A: Propyleenglycol is listed in official documentation, such as the Centers for Disease Control and Prevention (CDC) guidance, as one of the inactive ingredients (excipients) found in some vaccines.

Q: Why is Propyleenglycol sometimes referred to as '1,2-propanediol'?

A: The name 1,2-propanediol is the official chemical nomenclature used by chemists and in technical regulatory documents. Propyleenglycol is the more commonly recognized name, and both terms may be found in chemical and regulatory reference materials.

Q: What are the general principles for when Propyleenglycol is used as an inert ingredient?

A: The primary administrative principle set by regulatory authorities is that the total daily amount of Propyleenglycol received by a patient from all medicinal sources must not exceed the age-specific Maximum Daily Exposure (MDE) limits set for safety.

How should Propyleenglycol be stored and disposed of?

How to Store and Dispose of Propylene Glycol

Propylene Glycol, a pharmaceutical excipient, must be stored and disposed of according to specific regulatory and compendial requirements to maintain its quality and prevent environmental contamination.

Official Storage Requirements

Condition	Requirement (Official Statement)
Container	Must be preserved in tight containers and kept tightly closed due to its hygroscopic nature.
Environment	Store in a cool, dry, and well-ventilated place, protected from direct sunlight and elevated temperatures (generally not exceeding 40, C).
Safety	Store out of the sight and reach of children.

Official Disposal Requirements

Disposal of unused or expired product must be carried out via a licensed waste disposal contractor in compliance with applicable local and national environmental protection legislation. The product must not be released into drains, sewers, or waterways.

Propyleenglycol